How valid is a prescription-based multimorbidity index (Rx-risk) in predicting mortality in the Outcomes and Multimorbidity In Type 2 diabetes (OMIT) study? A nation-wide registry-based cohort study from Norway
Objective The prescription-based Rx-risk index has previously been developed to measure multimorbidity. We aimed to adapt and evaluate the validity of the Rx-risk index in prediction of mortality among persons with type 2 diabetes.Design Registry-based study.Setting Adults with type 2 diabetes in No...
Saved in:
| Main Authors: | Anne Karen Jenum, Jannicke Igland, Marjolein Memelink Iversen, Jan Ivar Røssberg, Ragnhild B Strandberg, Tore Julsrud Berg, Esben Selmer Buhl, Rachel Forster |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-03-01
|
| Series: | BMJ Open |
| Online Access: | https://bmjopen.bmj.com/content/14/3/e077027.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Correction: ‘How valid is a prescription-based multimorbidity index (Rx-risk) in predicting mortality in the Outcomes and Multimorbidity In Type 2 diabetes (OMIT) study? A nation-wide registrybased cohort study from Norway’
Published: (2024-12-01) -
Effects on HbA1c of referral of type 2 diabetes patients to secondary care
by: Kjersti Nøkleby, et al.
Published: (2025-04-01) -
Trends in incidence rates of acute myocardial infarction and stroke among immigrant groups in Norway, 1999–2019: the NCDNOR project
by: Kjersti Stormark Rabanal, et al.
Published: (2025-04-01) -
Multimorbidity in osteoarthritis
by: E. A. Taskina, et al.
Published: (2022-07-01) -
Management of multimorbidity
by: Alessio Bricca, et al.
Published: (2023-02-01)